Podcasts about Pharma

In 1971, the National Cancer Act transformed cancer into a national research priority. More than 50 years later, the next frontier is no longer defined solely by scientific discovery, but by how quickly knowledge, lived experience, and patient voices can reshape healthcare itself.The concluding chapter of The Cancer Mavericks: A History of Survivorship explores how the cancer advocacy movement continues to evolve in an era of digital communities, social media, precision medicine, and grassroots activism. Building on the work of pioneers such as Mary Lasker, Rose Kushner, and the generations of survivors who followed, today's advocates are expanding the movement beyond awareness to demand health equity, trusted information, patient-centered research, and meaningful representation in healthcare decision-making.The episode examines how technology has transformed advocacy from local support groups into global communities capable of organizing in real time. Researchers, policymakers, nonprofit leaders, and survivors reflect on the growing influence of digital storytelling, online education, and peer-to-peer networks that connect patients across diagnoses, generations, and geographic boundaries. At the same time, they acknowledge new responsibilities: ensuring accurate medical information, combating misinformation, protecting trust, and keeping patients at the center of innovation.The story also looks ahead to the next generation of advocates. Young leaders are applying lessons learned from decades of cancer activism while drawing inspiration from broader movements for social justice, public health, and community organizing. Their work reflects a simple but enduring truth: meaningful change rarely begins inside institutions. It begins when ordinary people refuse to accept that the system cannot improve.Cancer survivorship has never been a finished story. Every generation inherits the progress achieved by those who came before while confronting challenges uniquely its own. The future of survivorship will be shaped not only by scientific breakthroughs, but by those willing to listen, organize, educate, and ensure that every patient's voice helps define what comes next.RELATED LINKSNational Cancer Institute⁠Cancer Moonshot⁠Centers for Disease Control and Prevention | Division of Cancer Prevention and Control⁠HopeLab⁠Tigerlily Foundation⁠Stupid Cancer⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My client, Jennifer, spent four plus years as a clinical trial manager. Her leadership praised her, handed her work well above her level, and yet, her promotion didn't come. She had become too useful exactly where she was.Jen came into The Right Move Protocol with a one year goal. In just one month she had a promotion she was not expecting. A short time later she identified her ideal role with her dream company. By using the skills she learned and applying her growth mindset she negotiated and accepted an Associate Director position in a therapeutic area she had been trying to get into for years. She did it while her family had more going on than she ever could have anticipated.In this episode, you'll learn:What "developed in place" really means, and why the praise is not progressJen's 90% rule for deciding before you feel readyWhy the part of the program she dreaded is the part that got her results the quickestWhat she says to anyone who thinks her results were luck or timingThe negotiation truth that follows you from job to jobConnect with Jennifer on LinkedIn here.Get the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here.Work with Me: Learn more and apply to work with me here.Love the podcast?  Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

In 1987, Mary P. Lovato, a member of Kewa Pueblo in New Mexico, was diagnosed with acute leukemia. To receive a bone marrow transplant, she had to travel more than 800 miles from home because specialized cancer care was unavailable through the Indian Health Service. When she returned, she discovered another obstacle: many in her community feared cancer so deeply that they avoided speaking about it altogether.This episode examines how cancer survivorship exposed profound inequities in the American healthcare system. Long before health equity became a national priority, advocates from underserved communities were confronting disparities rooted in geography, poverty, racism, language, underfunded healthcare systems, and historical mistrust of medical institutions. Their work demonstrated that scientific advances alone cannot improve survival if patients cannot reach, afford, or trust the care available to them.The story follows pioneers including Mary P. Lovato, who built the first national Native-led cancer support and education program for Indigenous communities, and Maimah Karmo, founder of the Tigerlily Foundation, whose breast cancer diagnosis inspired a movement to improve early detection, clinical trial participation, and representation for Black women. Their advocacy challenged longstanding barriers to culturally competent care while highlighting persistent inequities in access to screening, fertility preservation, navigation, and innovative treatments.The episode also explores why diversity in clinical research matters. For decades, many cancer clinical trials disproportionately enrolled White patients, limiting both access to promising therapies and the scientific understanding of how treatments perform across different populations. Researchers, patient advocates, and community leaders responded by redesigning outreach, improving patient navigation, reducing logistical barriers, and insisting that affected communities help shape the research itself.Cancer survivorship cannot be measured solely by scientific breakthroughs. It also depends on whether every patient has a meaningful opportunity to benefit from them. The pursuit of health equity remains one of the defining challenges and enduring responsibilities of modern oncology.RELATED LINKSNational Cancer Institute | Cancer Health Disparities⁠Indian Health Service⁠Tigerlily Foundation⁠National Cancer Institute | Cancer Clinical Trials⁠American Indian Cancer Foundation⁠Abramson Cancer Center | University of Pennsylvania⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Per BioXcel's press release:BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva PharmaceuticalsAug 28, 2026 PDF VersionBioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholdersTeva Pharmaceuticals to serve as “stalking horse” bidder in a court-supervised 363 auction processBioXcel Therapeutics has secured a commitment for debtor-in-possession (DIP) financing to support ongoing operationsNEW HAVEN, Conn., Aug. 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel Therapeutics” or the “Company”), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH (“Teva”), a subsidiary of Teva Pharmaceutical Industries Ltd., for substantially all of the Company's assets. This includes IGALMI® (dexmedetomidine) sublingual film and the related pending supplemental New Drug Application of BXCL501 for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Concurrent with the execution of the asset sale agreement, BioXcel Therapeutics and its subsidiaries, OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC, have commenced voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the District of Delaware (the “Court”) to facilitate a court-supervised sale process, which is expected to include the auction of substantially all of the Company's assets.To anchor the sale process, Teva will serve as the sole “stalking horse bidder” for the sale of the assets contemplated by the asset sale agreement. A stalking horse asset sale agreement establishes a strong baseline offer and is intended to help maximize value for all stakeholders through the Chapter 11 auction process.“Following a comprehensive review of strategic alternatives, we believe this option provides a clear framework to pursue a value-maximizing transaction” said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. “Our priority is to execute a disciplined and efficient sale process while supporting all of our stakeholders and continuing to support the sNDA with a PDUFA date of November 14, 2026. We are pleased to have a signed agreement with a leading pharmaceutical company to serve as stalking horse bidder in the process, underscoring the strategic interest in our assets and in IGALMI®....”For the rest of the BioXcel press release see: https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-enters-asset-sale-agreement-tevaFor more information about the BioXcel bankruptcy/sale including the bankruptcy petitions and information about company assets and liabilities see: https://cases.stretto.com/bioxcel/ Typically, in situations such as these, there is a proposed buyer referred to as a stalking horse, and there is also an opportunity for other parties to come forward and bid on the assets.

In this episode of The Canadian Investor Podcast, we do a deep dive on two companies we haven’t covered much before: Royalty Pharma and AppLovin. We start with Royalty Pharma, a unique business that finances pharmaceutical and biotech products in exchange for future royalty streams. We break down how the business model works, why it has similarities to precious metals royalty companies like Franco-Nevada, and how investors should think about portfolio receipts, cash flow, milestone payments, drug approval risk, concentration risk and capital allocation. We then turn to AppLovin, one of the most talked-about stocks in the market. We look at how its AI-powered mobile advertising platform works, why the company generates extremely high margins with minimal capital expenditures, and what makes the business so profitable. We also discuss the risks facing AppLovin, including slowing growth, competition from Meta, Apple and Alphabet, concerns raised by short sellers, and why the market is having such a hard time valuing the company after a massive run-up and sharp drawdown. Tickers discussed: RPRX, APP, FNV.TO, WPM.TO, ISRG, META, GOOGL, GOOG, TTD Subscribe to our Our New Youtube Channel! Check out our portfolio by going to Jointci.com Our Website Our New Youtube Channel! Canadian Investor Podcast Network Twitter: @cdn_investing Simon’s twitter: @Fiat_Iceberg Braden’s twitter: @BradoCapital Dan’s Twitter: @stocktrades_ca Want to learn more about Real Estate Investing? Check out the Canadian Real Estate Investor Podcast! Apple Podcast - The Canadian Real Estate Investor Spotify - The Canadian Real Estate Investor Web player - The Canadian Real Estate Investor Asset Allocation ETFs | BMO Global Asset Management Sign up for Fiscal.ai for free to get easy access to global stock coverage and powerful AI investing tools. Register for EQ Bank, the seamless digital banking experience with better rates and no nonsense.See omnystudio.com/listener for privacy information.

Today we're talking about influencer marketing - and about the point where creator content stops being a brand play and starts being a performance channel. Creator-led ads run four times better on click-through rate than the same brand's own ads. So the question is no longer whether to use influencers. It's how to scale them without losing the ROI. In this episode, we bring you a live panel hosted by Lucia Aguilar, CEO and Founder at TATAM Digital, featuring: Joanna Malecka, Partnership Director at Numan Esma Ebnu, Influencer Marketing at Flo Health Lia Darozhkina, Senior Influencer Marketing Manager at Trade Republic Stephanie Terziyski, Growth Influencer Marketing Manager at HelloFresh. The panel works through four trends. YouTube as the new TV - 13% of all US viewership and more ad revenue than Paramount, Disney, Universal, and Warner combined - and why long-form still converts for products that need explaining. Creator and partnership ads, where content boosted from the creator's own handle beats anything posted from a brand account. Regulation, with only 57% of UK paid posts tagged correctly, and how teams in health, Pharma, and banking build compliance into the brief instead of bolting it on at sign-off. And AI, from sourcing and brief writing through to forecasting campaign results, plus the case for human creators in a feed filling up with avatars. If you work in influencer marketing, user acquisition, or performance marketing, this is a practical look at where creator budgets are going in 2026 and what it takes to scale them profitably. The panel's topics include: AI in growth teams — which tasks it already replaces, and why humans still own strategy Performance marketing's limits — why trust-driven categories like fintech need brand channels too Web-to-app funnels — near-double conversion rates and skipping the 30% app store tax Channel strategy for 2026 — fewer channels done better vs. always testing new ones Data and targeting vs. creative — where each wins, and the 96% CPA reduction story

Frankie Val builds the whole night around a question posed by a voice note from Kenny in Cleveland: is polite society already gone? Kenny describes a neighborhood that now feels like a GTA lobby, and a moment of hesitating to help a stranger for fear of being mistrusted, which Frankie treats as the real warning sign of breakdown. From there it sharpens. Frankie lays out his non negotiable line on law and order (commit violence and you are damaged goods, full stop) while insisting we still examine the larger factors nobody wants to touch, chiefly pharma and SSRIs, and the selective way media frames white male shooters versus everyone else. It is not all heavy. Expect a scattering of lighter fare, from a Betelgeuse companion star and a viral "jellyfish on Mars" to the absurd GTA 6 leak rumors, plus callers pitching black widow encounters and postpartum stories. Raffle and Saturday sleepover show teased.

As Fierce Pharma Week approaches, the Fierce Pharma Marketing team is taking stock of some of the biggest trends reshaping how drugmakers and healthcare agencies reach audiences. In this week’s episode of “The Top Line,” Fierce’s Ben Adams and Zoey Becker discuss how pharma marketing is evolving across social media, creative work and agency strategy. They dig into the changing approach to HIV marketing, pharma’s experiments with platforms including Snapchat, and what a collaboration with MrBeast says about the industry’s efforts to reach new audiences. They also examine how healthcare agencies are putting AI to work, pharma’s return to the winner’s circle at Cannes and why Novo Nordisk built a maze along the River Thames in London this summer. The conversation comes as Fierce Pharma Week approaches Sept. 14-17 in Philadelphia. To learn more about the topics in this episode: YouTuber MrBeast welcomes Amgen to the channel, kicking off pediatric cancer funding effort Inside agency view: Real Chemistry’s Frank Mazzola on audience nuance and rewarding creativity Snapchat creates ad format to support pharma disclosure needs Novo Nordisk asks public to ‘Meet Me in the Middle’ in new obesity experience installation Women’s ‘new health ecosystem’ takes shape on Reddit: report See omnystudio.com/listener for privacy information.

A battle erupts between RFK Jr. and Pennsylvania Governor Josh Shapiro over two “measles-associated” deaths, vaccine misinformation, and the use of abortion-derived fetal cell lines in MMR production.Jefferey Jaxen investigates Merck's claim that fulfilling President Trump's order to split the MMR vaccine could take up to a decade. Plus, Fauci launches a legal defense fund as scrutiny of the COVID lab-leak cover-up intensifies.As closing arguments conclude in the Lindsay Clancy trial, Del sits down with board-certified clinical psychologist Dr. Roger McFillin to examine Clancy's psychiatric-drug history and ask whether the pharmaceutical industry belongs on trial, too.Then, Del checks in with MAPS President Dr. James Neuenschwander about a MAPS physician's appointment to the NIH and the upcoming MAPS conference.Guests: Aaron Siri, Esq., James Neuenschwander, M.D., Roger K. McFillin, Psy.D., ABPPAirdate: August 27, 2026Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

In 2000, Katie Couric underwent a live colonoscopy on national television following the death of her husband, Jay Monahan, from colorectal cancer at age 42. The broadcast demystified a procedure many Americans feared, led to an estimated 20% increase in colonoscopy screenings, and became one of the clearest examples of how public storytelling can change healthcare behavior.This episode examines how celebrities, journalists, filmmakers, and entertainers helped reshape the public conversation about cancer during a period when survivorship was becoming increasingly visible. As breakthroughs in targeted therapies, immunotherapy, and early detection allowed more people to live beyond cancer, public figures used their platforms to encourage screening, reduce stigma, and accelerate research. Their influence extended far beyond awareness campaigns, helping transform cancer from a private diagnosis into a national public health conversation.Central to this story is Laura Ziskin, the Hollywood producer behind Pretty Woman and the Spider-Man films, whose metastatic breast cancer diagnosis inspired the creation of Stand Up To Cancer. Working alongside Couric and leaders from entertainment, journalism, and biomedical research, Ziskin championed a new funding model that required multidisciplinary scientific collaboration, helping accelerate discoveries that contributed to multiple FDA-approved cancer therapies. The episode also highlights the advocacy of actor Patrick Dempsey, whose family's experience with ovarian cancer led to the creation of the Dempsey Center, expanding support for patients and caregivers beyond medical treatment.The story also asks what celebrity advocacy often leaves unsaid. Financial toxicity, caregiver burden, chronic pain, mental health, and the long-term effects of treatment rarely receive the same attention as dramatic diagnoses or breakthrough cures. As cancer survivorship continues to evolve, the greatest challenge may not be convincing people to care about cancer, but helping them understand what it truly means to live with and beyond it.RELATED LINKSStand Up To Cancer⁠Katie Couric Media⁠Dempsey Center⁠American Association for Cancer Research⁠National Cancer Institute⁠Dana-Farber Cancer Institute | Adult Survivorship Program⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sumitomo Pharma America treated its first patient in a Phase 1/2a clinical trial for an emerging retinitis pigmentosa (RP) treatment called DSP-3077. The clinical trial plans to treat 12 adults with one of two different doses to evaluate safety and effectiveness of the treatment among patients who have RP.

Send us Fan MailPhillip Swan is a dynamic, forward-thinking leader renowned for turning complex challenges into strategic opportunities. As Chief Product and Go-to-Market (GTM) Officer at The AI Solution Group, Phillip blends customer-centric go-to-market strategies with cutting-edge product development, leadership, and partnerships.01:19 Meet Phillip Swan 03:33 Wind River Systems 07:30 Responsible AI Solutions 08:25 3 Key Areas: Manufacturing, Financial, Pharma 10:22 AI on Quicksand 11:30 AGI in 6 Months. Seriously? 13:08 The Definition of AGI 14:32 A Responsible AI Culture 19:51 Is Regulation the Catalyst? 21:57 AI Change Management 24:24 Phillip and the AI Group 25:33 AI Solution Group 29:16 Achieving Responsible AI 30:36 Clean Data 36:16 What Scares the Responsible AI Guy 39:36 Shadow AI 40:54 A SummaryLinkedIn: https://www.linkedin.com/in/phillip-swan/ Website: https://www.theaisolutiongroup.ai/Want to be featured as a guest on Making Data Simple?  Reach out to us at almartintalksdata@gmail.com and tell us why you should be next.  The Making Data Simple Podcast is hosted by Al Martin, WW VP Technical Sales, IBM, where we explore trending technologies, business innovation, and leadership ... while keeping it simple & fun. 

Send us Fan MailPhillip Swan is a dynamic, forward-thinking leader renowned for turning complex challenges into strategic opportunities. As Chief Product and Go-to-Market (GTM) Officer at The AI Solution Group, Phillip blends customer-centric go-to-market strategies with cutting-edge product development, leadership, and partnerships.01:19 Meet Phillip Swan 03:33 Wind River Systems 07:30 Responsible AI Solutions 08:25 3 Key Areas: Manufacturing, Financial, Pharma 10:22 AI on Quicksand 11:30 AGI in 6 Months. Seriously? 13:08 The Definition of AGI 14:32 A Responsible AI Culture 19:51 Is Regulation the Catalyst? 21:57 AI Change Management 24:24 Phillip and the AI Group 25:33 AI Solution Group 29:16 Achieving Responsible AI 30:36 Clean Data 36:16 What Scares the Responsible AI Guy 39:36 Shadow AI 40:54 A SummaryLinkedIn: https://www.linkedin.com/in/phillip-swan/ Website: https://www.theaisolutiongroup.ai/Want to be featured as a guest on Making Data Simple?  Reach out to us at almartintalksdata@gmail.com and tell us why you should be next.  The Making Data Simple Podcast is hosted by Al Martin, WW VP Technical Sales, IBM, where we explore trending technologies, business innovation, and leadership ... while keeping it simple & fun. 

James Sapirstein, CEO of CoCrystal Pharma, is developing a platform of antiviral therapies to treat norovirus, influenza and other viruses.  Norovirus, commonly transmitted on cruise ships and in dormitories, currently lacks effective vaccines or treatments. CoCrystal's oral small-molecule approach aims to treat active infections by reducing viral shedding duration and provide prophylactic prevention using a novel mechanism that targets viral entry points to prevent replication. James explains, "At CoCrystal Pharma, we have a platform of antiviral programs. The first program is for norovirus, and we have another program for influenza A. And then we also have a platform for rhinovirus, which is also many times referred to as the common cold. There's really not much out there."   "Norovirus is commonly known on cruise ships and in dormitories, college dormitories, and really it spreads by touch. That's why, when cruise ships have an outbreak of norovirus, if people haven't washed their hands or they touch an area where someone has touched that area before with active norovirus, they can get infected. And because people touch their faces over a thousand times, literally in a couple of hours, it's easy to transmit the virus."   "But there's also chronic norovirus, which people don't really talk about much because it's mostly in the nursing homes and assisted living areas, where some of these patients really suffer, and they're septic for a very long period of time. And they're not tested to see if they have norovirus because they have so many other health issues that people just aren't tested correctly." "Most antivirals, for the most part, work on the RNA. They cleave off the RNA, or they cleave off the cell membrane so that it doesn't replicate and the virus dies off. For us, it's much more specific. We like to call it a pocket where the virus enters the cell. We design a drug to specifically kill the virus at certain aspects within the virus, and then it doesn't allow it to replicate. And that's the way it's designed." #CoCrystalPharma #Norovirus #Antivirals #DrugDiscovery #InfectiousDiseases cocrystalpharma.com Download the transcript here

James Sapirstein, CEO of CoCrystal Pharma, is developing a platform of antiviral therapies to treat norovirus, influenza and other viruses.  Norovirus, commonly transmitted on cruise ships and in dormitories, currently lacks effective vaccines or treatments. CoCrystal's oral small-molecule approach aims to treat active infections by reducing viral shedding duration and provide prophylactic prevention using a novel mechanism that targets viral entry points to prevent replication. James explains, "At CoCrystal Pharma, we have a platform of antiviral programs. The first program is for norovirus, and we have another program for influenza A. And then we also have a platform for rhinovirus, which is also many times referred to as the common cold. There's really not much out there."   "Norovirus is commonly known on cruise ships and in dormitories, college dormitories, and really it spreads by touch. That's why, when cruise ships have an outbreak of norovirus, if people haven't washed their hands or they touch an area where someone has touched that area before with active norovirus, they can get infected. And because people touch their faces over a thousand times, literally in a couple of hours, it's easy to transmit the virus."   "But there's also chronic norovirus, which people don't really talk about much because it's mostly in the nursing homes and assisted living areas, where some of these patients really suffer, and they're septic for a very long period of time. And they're not tested to see if they have norovirus because they have so many other health issues that people just aren't tested correctly." "Most antivirals, for the most part, work on the RNA. They cleave off the RNA, or they cleave off the cell membrane so that it doesn't replicate and the virus dies off. For us, it's much more specific. We like to call it a pocket where the virus enters the cell. We design a drug to specifically kill the virus at certain aspects within the virus, and then it doesn't allow it to replicate. And that's the way it's designed." #CoCrystalPharma #Norovirus #Antivirals #DrugDiscovery #InfectiousDiseases cocrystalpharma.com  Listen to the podcast here

In 2006, a landmark report titled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer confirmed what young survivors had been saying for years. While survival rates for children and older adults had steadily improved, adolescents and young adults had experienced decades of stalled progress. They had become cancer's lost generation.This episode explores how young adult survivors transformed their shared isolation into one of the most influential grassroots movements in cancer advocacy. Diagnosed during the years typically devoted to education, careers, relationships, and starting families, patients between the ages of 15 and 39 confronted challenges that extended far beyond treatment. Fertility preservation, sexual health, employment, financial toxicity, insurance, and long-term quality of life were rarely discussed in oncology clinics, leaving many to navigate survivorship alone.The episode follows advocates including Tamika Felder, Lindsay Avner, Heidi Adams, Doug Ulman, and Dr. Archie Bleyer, whose research and advocacy fundamentally changed how medicine understands adolescent and young adult cancer. Through organizations including Planet Cancer, Fertile Hope, the Lance Armstrong Foundation, and later Stupid Cancer, survivors built online communities, educational resources, conferences, and national partnerships that challenged long-standing assumptions about cancer care. Their work helped establish fertility preservation as a standard discussion before treatment, expanded research dedicated to adolescent and young adult oncology, and elevated quality of life as a critical clinical outcome alongside survival.The movement also demonstrated the power of lived experience to reshape medicine. Survivors became researchers, educators, nonprofit founders, and policy advocates, insisting that cancer care account not only for years of life saved, but for the lives patients hoped to build afterward.What began as a search for peers evolved into a national movement that permanently transformed adolescent and young adult oncology. Today, dedicated research programs, clinical fellowships, survivorship resources, and patient advocacy organizations continue to build on the foundation these young cancer mavericks created.RELATED LINKSNational Cancer Institute | Adolescent and Young Adult (AYA) Cancer Program⁠Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer⁠American Society of Clinical Oncology | Fertility Preservation Guidelines⁠Stupid Cancer⁠Livestrong Foundation⁠Journal of Adolescent and Young Adult Oncology⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode looks back at APSS Sleep 2026 with Dr. Gerald George Mannikarote, Emerson Kerr, and Robert Miller. The conversation focuses on how the conference reflected a shift in sleep medicine toward more options, more pharmaceutical involvement, and a stronger need for technologists to stay grounded in fundamentals.We discuss why the live conference experience still matters, how AI and automation are changing scoring and diagnosis, and why pharmacy, telehealth, oral appliances, and new reimbursement codes are reshaping the future of sleep care.Chapters1 - Welcome to the APSS Sleep 2026 annual review2 - Baltimore conference turnout and the return of large in-person meetings3 - Emerson hands off the AST presidency to Massey Arrington4 - Why fundamentals matter in an AI-driven sleep industry5 - Scoring, false positives, and the risk of trusting automation too much6 - Why technologists must keep learning beyond the basics7 - Pharma's growing footprint on the exhibit floor8 - Home PSG systems and the coming CPT code changes9 - Sleep apnea, GLP-1s, and the move toward precision therapy10 - Why the old CPAP-only pathway no longer fits every patient11 - Seven treatment options and the challenge of choosing the right one12 - Why failed protocols and failed home sleep tests need rethinking13 - Pharmacy as a new screening and referral gateway14 - Why more entry points could help more patients get treated15 - Where the future of sleep medicine is headed16 - Moving from AHI alone to why a patient has sleep-disordered breathing17 - Why mild OSA may benefit from earlier non-CPAP treatment18 - Oral appliance therapy education gaps and first-line use19 - A mild OSA patient who benefited from an oral appliance after CPAP struggle20 - Consumer tech, awareness, and the Rise of sleep telehealth referrals20 - Why local sleep conferences still matter for technologists21 - Sleep navigation, education, and where technologists fit in the new model22 - Future guests, new projects, and what to expect next from the showA huge thanks to our sponsors:Fisher & Paykel Healthcare  Discover how F&P full-face masks have led millions of people to a great night's sleep at https://www.fphcare.com/curiosityhttps://www.fphcare.com/us/homecare/sleep-apnea/Philips Healthcare  See how Philips is supporting you and your patients with meaningful innovation. Visit https://www.philips.com/matters Soliish https://www.soliish.com/React Health  https://www.reacthealth.com/myWaveshttps://mywaves.tech/More resources for clinicians can be found at Sleep Review Magazine  https://sleepreviewmag.com/Credits:Intro Music: Pierce G. MannikaroteAudio/ Video: Diego R. MannikaroteHosts: J. Emerson Kerr, Robert Miller, Gerald George MannikaroteCopyright: ⓒ 2026 SleepTech Talk ProductionsEpisode 130The views and opinions expressed by guests on SleepTech Talk are their own and do not necessarily reflect those of the podcast hosts or SleepTech Talk as a whole. This podcast is intended for educational and informational purposes only and should not be considered medical advice. Listeners are encouraged to consult with a qualified healthcare professional for any medical concerns or questions.Don't forget to Like, Share, and Comment! Subscribe for more conversations with leaders shaping the future of sleep medicine, sleep technology, and patient care.

On this episode of Vitality Radio, Jared explores a heartbreaking and highly publicized case involving postpartum mental health struggles, multiple psychiatric prescriptions, and the devastating consequences that followed. Using publicly documented court records and prescription timelines, he examines the challenges of polypharmacy, fragmented care, and the importance of patients actively participating in their own health decisions. Jared also discusses research surrounding mental health, the gut-brain connection, nutrient status, methylation, and other foundational factors that may influence emotional well-being. Drawing from his wife Jen's personal journey, he shares a message of hope and resilience for those facing anxiety, depression, or other mental health challenges. This episode encourages listeners to ask questions, seek understanding, and explore a more comprehensive approach to supporting both body and mind.Additional Information:#264: Emotional Vitality: Jen's Story Part 1 - From Addiction and Mental Illness to Vitality#423: Emotional Vitality: Jen's Story Part 2 - Rebalancing Mind and Body Through Supplementation#438: Emotional Vitality: Jen's Story Part 3 - Weaning Off of Pharma#457: Emotional Vitality: Jen's Story Part 4 - How Changing Your Mindset Can Change Your Life #505: Emotional Vitality: Jen's Story Part 5 - The Impact of Diet on Mental Health and Physical Pain#601: Folate vs. Folic Acid and the Importance of B12 and B6 as the Methylation TeamVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.This podcast is produced by DrTalks.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drtalks.com/podcast-service/

In dieser Samstagsfolge von „Alles auf Aktien“ reden wir über den magischen mRNA-Moment. Erleben wir jetzt eine medizinische Revolution oder ist der Hype um Moderna und Biontech übertrieben? Die Antwort liefert unser Gast. Er investiert seit Jahrzehnten in Pharma und Biotech und weiß genau, wer jetzt zum Gewinner wird – wer zum Verlierer. Ihr bekommt von ihm den großen Vergleich der beiden Konkurrenten und vor allem seine Biontech-Analyse räumt mit großen Irrtümern auf. Außerdem nennt unser Profi die spannendsten Übernahme-Kandidaten, seine persönlichen Pharma-Perlen, gibt eine erstaunliche Novo-Nordisk-Prognose ab – und verrät, was er einst von Wassili Papas lernte. Ein Gespräch mit Markus Manns. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (8/21/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v7cb2wc","div":"rumble_v7cb2wc"}); Source Links (In Chronological Order): Sam Husseini Interview - Can A Corrupt System Be Changed From Within? New Tab (20) Brian Cates - Political Columnist & Pundit on X: "@L08818 I slowly came to realize on hanging out with Ron Paul enthusiasts that they don't want to reform the system, drive out the corruption, and restore the country. The want to...and they told me this several times, but back then I didn't really believe them...BURN IT ALL DOWN AND" / X (20) The Last American Vagabond on X: "What an absolutely disingenuous coward you are @L08818. https://t.co/31KRfbLcxZ" / X (20) SheThinksFreely (@L08818) / X (20) SheThinksFreely on X: "@TLAVagabond Bro GTFOH w this stupid sh*t Anarchy is anti American You traitorous piece of excrement" / X (20) SheThinksFreely on X: "

What does a biotech CEO who has brought eight orphan drugs to market have in common with a bestselling novelist? In this case, they are the same person. Today's guest is Fredric Price, who writes award-winning fiction as David Hirshberg. His newest novel "Crossing the Bronx" completes a trilogy that began with "My Mother's Son" and continued with "Jacobo's Rainbow." Price is living proof that remarkable lives show up everywhere. He's been a CEO for decades, founded a biotech firm after he thought he had retired, is a book publisher, and only started writing fiction past middle age. In this conversation we talk about why storytelling is the real skill behind both raising millions for a drug and writing a novel, the unforgettable 30-second video he showed the FDA that changed everything, why he uses 1952 and 1955 to talk about 2026, and why he has no desire to write a pharma thriller. This is an episode about second acts, about never actually retiring, and about the idea that the technical details are just the skeleton — story is the muscle, flesh, and eyes.Get your copy of Crossing the Bronx by Fredric PriceAs an Amazon Associate, Now I've Heard Everything may earn a commission from qualifying purchases.Chapters:00:00 Introduction and Guest Background 01:51 Fredric Price's Diverse Career and Passions 05:00 The Skeleton and Flesh of a Good Story 07:41 Using History to Reflect the Present 11:11 Themes of Family and Rivalry in His Novels 13:24 Writing Without Being Handcuffed by History 14:45 Comparison of Satisfaction: Novels vs FDA Approval 16:13 Recognition and Success in Writing and Pharma 17:35 Future Projects and Reinventions 18:47 Closing Remarks and AppreciationGuest InformationFredric PriceWebsite1999 interview with Barry Gibbons For more intriguing and engaging interviews each week, subscribe now on:Spotify Apple Podcasts YouTube

In 2006, the Institute of Medicine published From Cancer Patient to Cancer Survivor: Lost in Transition, concluding that millions of Americans were surviving cancer only to find themselves navigating a healthcare system unprepared for life after treatment. The report challenged oncology to recognize that curing cancer was not the end of care, but the beginning of survivorship.This episode explores how the growing cancer survivorship movement exposed the long-term consequences of cancer treatment that medicine had largely overlooked. As survival rates improved following the National Cancer Act of 1971, millions of survivors faced chronic fatigue, neuropathy, infertility, cognitive impairment, financial hardship, employment discrimination, anxiety, depression, and post-traumatic stress. These were not rare complications. They became defining features of survivorship for many patients.Drawing on the work of oncologist Dr. Patricia Ganz, survivor advocate Ellen Stovall, and researchers, clinicians, and survivors across the country, the episode examines how survivorship research expanded beyond recurrence and mortality to include quality of life, psychosocial care, rehabilitation, and long-term follow-up. Their efforts helped establish survivorship care plans, multidisciplinary survivorship clinics, and a broader understanding that cancer affects every aspect of a person's life long after treatment ends.The episode also confronts persistent inequities in survivorship care. Insurance coverage often ends when treatment stops, supportive services remain inconsistent, financial toxicity continues to drive medical hardship, and racial, geographic, and socioeconomic disparities still influence who receives comprehensive follow-up care. For many survivors, finishing treatment simply marks the beginning of another struggle.Modern oncology increasingly recognizes that surviving cancer is measured by more than years of life. It is also measured by quality of life, dignity, access to care, and the ability to rebuild a future after treatment. That evolution remains one of the most significant legacies of the cancer survivorship movement.RELATED LINKSNational Academy of Medicine | ⁠From Cancer Patient to Cancer Survivor: Lost in Transition⁠National Cancer Institute Office of Cancer Survivorship⁠American Society of Clinical Oncology | Survivorship Compendium⁠CancerCare⁠HopeWell Cancer Support⁠National Coalition for Cancer Survivorship⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of the podcast is a wake-up call for Americans, as the host delves into the country's alarming debt crisis and the consequences of inaction. With the national debt doubling in just ten years, from $20 trillion to $40 trillion, the host argues that the situation is dire and requires immediate attention. The guest, JD Hayworth, a former congressman and current advocate for the Pharmaceutical Reform Alliance, joins the conversation to discuss the need for "most favored nation" status for the US when it comes to drug prices. The host and JD Hayworth discuss the shocking differences in drug prices between the US and other countries, with Americans paying an average of $936 per month for certain medications, compared to $147 in Canada and $93 in the UK. They also explore the potential savings of $600 billion over the next decade if the US were to adopt most favored nation status. The conversation highlights the urgent need for reform and the importance of putting American interests first. Meanwhile, the host also touches on other pressing issues, including the rise of bears in Colorado, the importance of education, and the need for accountability in government. The episode is a thought-provoking and informative discussion that will leave listeners questioning the status quo and considering the future of the country. The Rex Run for Pawsitivity is Sept 5th and has something for the whole family. If you’ve got a pup with law enforcement dreams, at RexRun you can fulfill their very dream. They have a package complete with a badge, personalized certificate and live swearing in ceremony with Arapahoe County Sheriff Tyler S. Brown! There is also a 5k trail run or walk and so much more. Find the details here, and Sheriff’s Deputy Jon Gray will be in with Rex today at 2:30.See omnystudio.com/listener for privacy information.

Moderna und Merck erfreuen nicht nur Patienten mit guten Ergebnissen eines Krebsimpfstoffs - sondern auch ihre Aktionäre. Um 176 Prozent sprang die Moderna-Aktie gestern. Auch, weil es hier um mehr als einen Impfstoff geht.

If their products are so revolutionary, so safe and effective, why does Big Pharma have to spend $36 billion a year to convince us to take them? The jaw-dropping revenue the big pill makers drop on influencing public opinion and - this is my take - keeping you sick and addicted. A remarkable mashup flash back to the "influencers" shaming you for doing your own research. PLUS democrats have a plan to win the midterms and boy, is it a doozy.     

You put together the strategy your VP loves, then your own manager tears it apart, and you're left standing in the middle with no one publicly on your side. Or your name isn't in the meeting where decisions about your own project get made, and you find out after the fact what everyone else already agreed to. In pharma and biotech, matrix teams and shifting priorities make this common, not personal, and most women read it as proof there's nothing they can do. That belief is the actual problem. This episode breaks down exactly what to do about it, so you stop waiting for the room to change and start leading it.In this episode, you'll learn:Why conflicting feedback from your stakeholders isn't a dead endThe real reasons you get left out of decision-making meetingsHow to get buy-in from a stakeholder who doesn't think like you doWhat radical responsibility looks like when no one seems to have your backThe three-step shift I coach inside The Right Move Protocol every weekGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here.Work with Me: Learn more and apply to work with me here.Love the podcast?  Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Send us Fan MailThis investor has spent decades doing one thing: buying right. From a 10,000-unit apartment portfolio sold to a major real estate buyer, to a pharmaceutical company purchased for $18M and exited at $358M, to two insurance companies flipped for significant returns - the track record is built on cash flow, not speculation. In this episode, he shares his full investment history and explains why today's market has made it nearly impossible to find the kinds of companies he used to target.With interest rates reshaping private equity valuations and private credit crowding out traditional buyers, he breaks down exactly where he's looking now: LP secondaries, continuation funds, and public market alternatives that offer the same exposure at a discount. If you're a capital allocator trying to find value in a premium-priced market, this conversation is essential.Recorded at the Single Family Office Summit, hosted by Family Office Club - the largest investor club in the family office space. 19 years, 300+ events, and over $1 billion in community transactions. Learn more and register for our next event at FamilyOffices.com.What's the most underrated opportunity in today's private market environment?https://familyoffices.com/

Tata 1mg just reported revenue of nearly 3,000 crore rupees for the last financial year, roughly ten times what it earned when Tata took control, and it is turning a profit while much of the sector bleeds cash. In an e-pharmacy market obsessed with 10-minute delivery and deep discounts, 1mg won by doing the opposite. It capped its discounts and built its own labs and supply chain, and it treats fast delivery as a minor add-on. In this episode, we unpack why patience beats blitzscaling in Indian healthcare and what 1mg means when it calls healthcare longitudinal.Take The Great Rewiring survey hereDaybreak is produced from the newsroom of The Ken, India's first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories.

THE BATTLE OF ACTS - 08.17.2026 - #967 BestPodcastintheMetaverse.com Canary Cry News Talk #967 - 08.17.2026 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers Chelsea S*** Sir LX Protocol Baron of the Berrean Protocol*** Nancy, An Awake (& Lonely) Boomer***   Producers of TREASURE (CanaryCry.Support) Rebecca T, Monica, Palmer C   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   SIR IKE MEGA BOX GIVEAWAY - Rating/Review, screenshot, send to Sir Ike CanaryCrySupplyDrop@gmail.com   ANTARCTICA 22:19 Antarctic fungi offer new hope for Alzheimer's drug discovery (Malay Mail)   NEPHILIM UPDATE 31:19 Extinct human remains found on seafloor fuel claims of real-life biblical giants (DailyMail)   EXECUTIVE PRODUCERS 46:38   WITCHCRAFT 1:02:33 Witch World: Queer Occultism Blooms in the Desert (Art Forum)   Jewish witchcraft isn't as weird as it sounds (Forward)   RE-ENCHANTMENT 1:51:59 The Daily Magical Life of Mesopotamia (Collector) Acts 8:9-24 : Simon Magus wanted to pay for the power of the Holy Spirit Acts 13:6-12 : Bar-Jesus the Magician (Elymas) is Blinded by the Holy Spirit Acts 16:16-18 : Slave Girl Oracle is exorcized, losing money for her masters Acts 19:18-20 : The Magicians of Ephesus burn their grimoires Acts 19:23-41 : The Craftsmen of Idolatry Riot  Ephesians 3:9-10 : When Paul writes to the congregation of ex-magicians in Ephesus, he says that their salvation is now    PRODUCERS 2:50:57 END 3:02:42

In 1967, breast surgeon Dr. Harold P. Freeman arrived at Harlem Hospital expecting to treat cancer. Instead, he confronted a healthcare system where poverty, racism, lack of insurance, and institutional barriers often determined who lived long enough to receive treatment. Patients frequently arrived with advanced disease, not because medicine lacked answers, but because access to care had failed them.This episode explores how cancer survivorship expanded beyond medical breakthroughs to include healthcare access, health equity, and organized advocacy. Building on the early work of the National Coalition for Cancer Survivorship (NCCS), it examines the recognition that surviving cancer depended not only on research, but also on whether patients could navigate a fragmented healthcare system.Freeman responded by creating one of the nation's first patient navigation programs at Harlem Hospital in 1990. Community-based navigators helped patients overcome practical barriers including insurance, transportation, appointments, communication, and fear. The model dramatically improved timely diagnosis and treatment, increased breast cancer survival in Harlem, and ultimately inspired the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005, establishing navigation as a cornerstone of modern oncology care.The episode also follows cancer survivor Ellen Stovall, whose leadership transformed survivorship into a national policy movement. Through the NCCS, she united advocates across cancer types, fought for insurance protections, expanded access to clinical trials, helped shape the creation of the Office of Cancer Survivorship at the National Cancer Institute, and organized the landmark 1998 National March for Cancer Survivorship in Washington, D.C. Her work reframed survivorship as a public policy issue rather than a personal experience.Together, Freeman and Stovall demonstrated that scientific progress alone could not eliminate disparities in cancer outcomes. Their work established two enduring principles that continue to shape oncology today: patients need someone to help them navigate care, and survivors must have a voice in the policies that govern it. Modern cancer survivorship depends on both.RELATED LINKSNational Coalition for Cancer Survivorship⁠Harold P. Freeman Patient Navigation Institute⁠National Cancer Institute Office of Cancer Survivorship⁠Patient Navigator Outreach and Chronic Disease Prevention Act of 2005⁠American Cancer Society⁠Tuskegee Study Timeline | Centers for Disease Control and Prevention⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's time to build your family's future on a foundation of true health and freedom. Join us at Future Foundations—because your future generations deserve the best start to the mission that will outlive us… Check it out here. Use code FREEDOM25 for 25% off!    Whether you're looking for tinctures, topicals or teas or a deeper connection to your INNATE healing capacity, Noble Task Homestead is here to serve you. Join the movement. Visit NobleTaskHomestead.com/noblestan today and enjoy a 10% discount on your order.   San Diego area residents, take advantage of our special New Patient offer exclusively for podcast listeners here. We can't wait to experience miracles with you!   Welcome to a new episode of the Future Generations Podcast. In this episode, Dr. Stanton Hom sits down with Alec Zeck, a powerful voice in the health freedom movement, to explore how trauma, sovereignty, and true healing intersect. Alec shares his raw story of growing up in an abusive home, losing his mother to the psychiatric system, then witnessing her and his wife's complete turnaround through food, trauma healing, and spiritual alignment outside the pharmaceutical model. Together, we explore "beautiful uncertainty," conscious reality creation, and a future where families reclaim medical freedom, bodily autonomy, and vibrant generational health.   Highlights: "While living through a period of massive uncertainty, we have the ability to consciously create our reality."    "I know my purpose: to help humanity navigate the narcissistic abuse it's experiencing at the hands of the pharmaceutical industry."    "After seeing what I've seen, reading what I've read, hearing what I've heard, and experiencing what I've experienced, there is no turning back."   "We are aligning our thoughts and our feelings and taking deliberate action for a more beautiful future."  Timestamps: 00:00 – Introduction 03:30 – Consciously Creating Reality Together 05:57 – Wealthy Practitioner & True Business Freedom 07:13 – Alec's Childhood: Abuse, Neglect, and Feeling Unworthy 11:10 – His Wife's Lupus, RA, and Drug-Free Healing 13:13 – Alec's Mission: Ending Pharma's Narcissistic Abuse Remember to Rate, Review, and Subscribe on iTunes and Follow us on Spotify!   Learn more about Dr. Stanton Hom on:   Instagram: https://www.instagram.com/drstantonhom    Website: https://futuregenerationssd.com/  Podcast Website: https://thefuturegen.com  Twitter: https://twitter.com/drstantonhom   LinkedIn: https://www.linkedin.com/in/stanhomdc   Stay Connected with the Future Generations Podcast:   Instagram:  https://www.instagram.com/futuregenpodcast   Facebook: https://www.facebook.com/futuregenpodcast/     About Alec Zeck : D. Alec Zeck is an independent researcher, speaker, writer, podcaster, former Army Captain, husband, and father of three. He is best known for his popular podcast The Way Forward with Alec Zeck, one of the top-ranked shows in the alternative health space and top 0.5% amongst all podcasts worldwide. Alec is the Founder of The Way Forward—an organization and community platform that empowers men and women to reclaim their health, freedom, and sovereignty through education, decentralization, and real-world connection. The platform features a robust map-based directory to help users find like-minded individuals, practitioners, farms, businesses, and community hubs in their area. The desire to go off grid and have the ability to grow your own food has never been stronger than before. No matter the size of your property, Food Forest Abundance can help you design a regenerative layout that utilizes your resources in the most synergistic and sustainable manner. If you are interested in breaking free from the system, please visit www.foodforestabundance.com and use code "thefuturegen" to receive a discount on their incredible services.   Show your eyes some love with a pair of daylight or sunset (or both!) blue-light blocking glasses from Ra Optics. They have graciously offered Future Generations podcast listeners 10% off any purchase. Use code FGPOD or click here to access this discount, and let us know how your glasses are treating you!   One of the single best companies whose clean products have supported the optimal wellness of our family is Earthley Wellness. Long before there was a 2020, Kate Tetje and her team have stood for TRUTH, HEALTH and FREEDOM in ways that paved the way for so many of us. In collaboration with this incredible team, we are proud to offer you 10% off of your first purchase by shopping here.   Are you concerned about food supply insecurity? Our family has rigorously sourced our foods for over a decade and one of our favorite sources is Farm Match and specifically for San Diego locals, "Real Food Club PMA". My kids are literally made from their maple breakfast sausage and the amazing carnitas we make from their pasture raised pork. We are thrilled to share 10% off your first order when you shop at this link.   Another important way to bolster food security is by supporting local ranchers. Our favorite local regenerative ranch is Perennial Pastures. They have the best nutrient-dense meats that are 100% grass-fed and pasture-raised. You can get $10 off of your first purchase when you use the code: "FUTUREGENERATIONS" at checkout. Start shopping here.

Consumerization is changing how patients engage with healthcare, and pharma companies may need to rethink how they approach awareness, diagnosis and commercialization. In this sponsored episode of The Top Line, host Irena Luo is joined by Rachel Stoll, Managing Partner, Growth & Innovation at Princeton10, and Kevin Nalty, Vice President of Strategy at Princeton10, to discuss how evolving patient behaviors are reshaping the healthcare journey. Together, they explore the impact of GLP-1s, telemedicine, AI, wellness technologies and other low-friction healthcare experiences that are raising expectations for convenience and accessibility. The conversation examines emerging gaps between health awareness and clinical diagnosis, the role of wellness tools and health data, and why some patients delay or avoid care altogether. The guests also discuss opportunities for pharma brands to rethink disease awareness, improve navigation to diagnosis and treatment, and borrow engagement strategies from successful consumer platforms that encourage long-term behavior change. Listen to hear practical insights on how brand teams can adapt their commercial strategies, identify hidden friction points and better meet the needs of today's healthcare consumer.See omnystudio.com/listener for privacy information.

Welcome to a very, very, very special bonus episode of Out of Patients, and one unlike anything published on this feed before. For nearly 20 years, Matthew Zachary has handed these microphones to patients, caregivers, doctors, advocates, troublemakers, and people with something worth saying. This time, he handed them to his daughter. Hannah Greenzweig grew up around this show, and now she has commandeered the studio with 3 of her wonderfully creative high school friends to talk about something they built entirely themselves. There is an enormous amount of Dad Pride baked into this episode, along with the strange and wonderful realization that sometimes your kid grows up, takes your chair, takes your microphone, and produces a better show without you.Hannah Greenzweig, Michael Aidinov, Gwendolyn Baldini, and Astronomy are student artists from the Roundabout Youth Ensemble at James Madison High School in Brooklyn. Working alongside teaching artists from Roundabout Theatre Company, they spent a school year creating an original play from the ground up, writing every scene, developing every character, and producing the performance themselves.Instead of discussing a Broadway production, they dissect one they invented.Their play, Subject Matter, began with a room full of improbable ideas. Murderous bounce houses, pirate family sagas, underwater adventures, courtroom dance battles, and birthday parties at math museums all competed before the group settled on an absurd rivalry between New York's fictional History Museum and Math Museum. From there, they built a fully staged comedy about institutional competition, sabotage, oversized personalities, and the unexpected discovery that history and mathematics need each other more than either side wants to admit.The conversation pulls back the curtain on a creative process most audiences never see. The students explain how scenes evolved through constant rewrites, how characters emerged from improvisation, how costumes came together with last minute ingenuity, and how rehearsals often collapsed into uncontrollable laughter. They recount cutting favorite ideas, solving production problems with limited resources, and trusting each other enough to keep rewriting until the story worked.The episode also captures something harder to script: teenagers speaking honestly about collaboration without adults translating their experience. They celebrate classmates who stepped into unexpected roles, teachers who quietly held the production together, and the strange joy of creating something that exists only because everyone showed up.It is a conversation about theater, friendship, education, creativity, and what happens when 4 young artists get the microphones and the adults get out of the way.RELATED LINKSRoundabout Theatre CompanyRoundabout Youth EnsembleJames Madison High SchoolFEEDBACKLike this bonus episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mazen S. Darwazeh is the Executive Chairman and Deputy Chief Executive Officer of Hikma Pharmaceuticals, and a Jordanian senator currently serving his fifth term.His journey with Hikma began in 1985 as a medical representative.Over the next four decades, he rose through the company to lead its MENA business and help shape Hikma into the largest pharmaceutical company by sales in the region and a FTSE 100 multinational employing around 9,500 people across three continents.Recorded in Dalian, China, this conversation was made possible thanks to the World Economic Forum, who facilitated the episode during the Annual Meeting of the New Champions.On this episode, we talk about what it takes to preserve the values of a family-built company as it becomes a global institution, Hikma's ambitions for healthcare in the Middle East, the growing role of biosimilars and biotechnology, and the challenge of ensuring access to essential medicines in a region shaped by geopolitical uncertainty.We also discuss China's evolving role in the pharmaceutical industry, Mazen's perspective from both business and public service, and what four decades in healthcare have taught him about leadership, longevity and building something that lasts.

Get your CBD today at Emerald MED with 30% off up to 2 items: https://www.emeraldmedcbd.com/awk?ref=andweknow Last interview: https://tinyurl.com/bdhwpvza ————— Trusted Sentry H20 Water Filtration System: https://sentryh2o.com/awk RECENT INTERVIEW: https://tinyurl.com/yfnrtw63  ————— Grace Center Foundation: https://www.gracecenterfoundation.org/ ————— Protect your investments with And We Know http://andweknow.com/gold Or call 720-605-3900, Tell them “LT” sent you. ————————— ➜ Our AWK Website: https://www.andweknow.com/ ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ------- *DONATIONS SITE: https://bit.ly/2Lgdrh5 *Mail your gift to: And We Know 30650 Rancho California Rd STE D406-123 (or D406-126) Temecula, CA 92591 ➜ AWK Shirts and gifts: https://shop.andweknow.com/ ➜ Audio Bible https://www.biblegateway.com/audio/mclean/kjv/1John.3.16 Connect with us in the following ways:

A man is struck by a car on the streets of Los Angeles. In the emergency department, a CT scan ordered to look for traumatic injuries reveals something nobody expected: a mass in his colon. Days later, sitting across from Dr. Belinda Waltman, he calls the accident “a blessing in disguise.” Then he changes the subject. He is less worried about cancer than about whether he can afford to miss another day of work. In this season finale of Standard Deviation, host Dr. Oliver Bogler explores what happens when biomedical science collides with the realities of the healthcare safety net. Dr. Waltman, a primary care physician in Los Angeles County, specializes in expedited cancer workups for uninsured and underinsured patients. Every diagnosis arrives carrying another set of questions about housing, transportation, food insecurity, wages, and survival that rarely appear in medical records or scientific literature. For years, Waltman carried those stories without knowing how to bring them into the academic record. As a full-time clinician without a research lab, grant funding, or publication pipeline, she faced barriers familiar to many working scientists and physicians whose most important observations happen outside traditional research settings. With support from the Life Science Editors Foundation's JEDI program, those experiences became The Margins Matter, a narrative medicine essay published in JAMA that argues the social realities surrounding cancer care are not background details. They are part of the disease itself. Bogler traces how editorial mentorship transformed lived clinical experience into published scholarship while asking a larger question about who gets to shape the scientific record. The conversation examines cancer care, Medicaid, health-related social needs, medical publishing, and the structural incentives that determine which stories become evidence and which disappear from view.The result is a conversation about documentation, visibility, and why the margins of medicine often determine who survives long enough to benefit from its advances.RELATED LINKSDr. Belinda Waltman⁠The Margins Matter | JAMA⁠The Margins Matter | PubMed⁠Life Science Editors Foundation⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

How do you take a model that works in process development and get it accepted for use in GMP manufacturing? That question stalls most bioprocess modeling projects before they start. Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, pushes back on the premise: the process you run today is already governed by a mathematical model, fitted once at small scale during process characterization and then left untouched for years, even as the process shifts.Part 1 separated digital models from digital shadows and digital twins, and made the case for starting with the decision rather than the data. Part 2 goes into the plant: what regulators actually require, what the numbers looked like on a real biologics process, and where a team should start on Monday morning.Topics covered:Core differences—and surprising similarities—between modeling in development versus manufacturing (02:35)Regulatory requirements: credibility assessments, model risk, and validation steps for digital twins (05:07)Real-world example: How deploying an end-to-end process model led to 35% yield increase for Takeda, and considerations for ROI in manufacturing (08:34)Advice for startup leaders on when to invest in modeling and how to scale efforts case-by-case (11:42)Steps for scientists new to modeling: identifying bottlenecks, starting simple, and proving value offline before scaling up (12:26)The importance of understanding basic statistics before relying on AI-generated models (15:22)A stepwise summary for deploying digital modeling effectively in biotech (16:01)Smart insight: The digital twin is the last step, not the first. Identify the bottleneck, build the simplest model that supports the decision, and concatenate it end to end so you can see how a parameter moves final drug substance quality rather than one unit operation's output. Prove the value offline. Only then connect interfaces, because that is where the cost and the validation burden live. Teams that lead with the twin arrive at the C-level with a proof of concept and no evidence. Teams that lead with the offline model arrive with a number.Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del ValEpisodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyConnect with Ignasi Bofarull-Manzano:LinkedIn: www.linkedin.com/in/ignasi-bofarullKörber Pharma website: www.koerber-pharma.comSupport the show

August 12, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Hims CEO Andrew Dudum says the company plans to offer approved peptides by year-end, leveraging 19% subscriber growth to 2.9 million as a distribution channel Abbott's Lingo glucose data integrates with Google Health's AI Coach, joining Abbott's Whoop investment and Lilly's Oura stake in the race to connect health data AWS becomes Novo Nordisk's strategic AI partner, launching a joint hub as Amazon's Bio Discovery platform accelerates drug development alongside NVIDIA and OpenAI Today's episode is brought to you by AIIR — a modern communications and experiential agency for health, wellness, fitness, and performance brands. From earned media to events and creator-led campaigns, AIIR helps companies sharpen their story, earn attention, and build trust that compounds. Visit https://aiir.agency to learn more. More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe  Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider  Reach out → insider@fitt.co 

MichaelAaron and Richard explore why half of chronic-illness patients skip their medication, and why scaring them into compliance backfires. They cover a study on avoiding bad medical news, a simple diagram that cut medication errors in half, and two studies showing doctors are swayed by menu order and time of day when prescribing.

Today On The Eric Metaxas Show, James Howard Kunstler joins Eric to discuss Anthony Fauci's recent testimony, the unanswered questions surrounding Covid, and whether accountability may finally be coming. They also examine the roles of government agencies, media organizations, pharmaceutical companies, January 6, the Biden-era DOJ and FBI, and the broader collapse of trust in American institutions. Kunstler argues that despite widespread frustration and “black-pilling,” the truth is durable and the wheels of justice may still be turning.⭐ ORDER NOW:Revolution: The Birth of the Greatest Nation in the History of the World

In 1986, 23 survivors, physicians, nurses, attorneys, and community organizers gathered in Albuquerque, New Mexico, for a weekend that would permanently change the language and politics of cancer. Working late into the night, they debated not only strategy, but identity, ultimately declaring that from the moment of diagnosis, every person with cancer is a survivor.This episode traces the social and political forces that gave birth to the modern cancer survivorship movement. As advances in early detection and treatment allowed more people to live beyond cancer, survivors discovered that finishing treatment did not mean returning to normal life. Many faced employment discrimination, loss of insurance, social stigma, infertility, chronic health complications, and a healthcare system that viewed survival as the end of care rather than the beginning of a new chapter.Against the backdrop of the civil rights, disability rights, and community health movements of the 1960s and 1970s, physicians, activists, and survivors challenged medicine's paternalistic culture and demanded a greater voice in decisions affecting their lives. Central to this story are physician and survivor Dr. Fitzhugh Mullan, whose landmark 1985 essay, Seasons of Survival, redefined survivorship as a lifelong continuum, and community organizer Katherine Logan, whose determination united dozens of grassroots organizations into what became the National Coalition for Cancer Survivorship.The coalition's founding established principles that continue to shape oncology today. Survivors were no longer defined solely by disease or treatment outcomes. Their experiences became evidence. Their voices became essential to clinical research, healthcare policy, and patient advocacy. By redefining survivorship as an ongoing experience rather than a destination, the movement challenged medicine to recognize the lasting physical, emotional, financial, and social consequences of cancer.The ideas forged during that weekend in Albuquerque became the foundation of modern cancer survivorship. Nearly 40 years later, the coalition's defining principle, that survivorship begins at diagnosis, continues to influence cancer care, research, policy, and the way millions of people understand life after cancer.RELATED LINKSNational Coalition for Cancer Survivorship⁠National Cancer Institute Office of Cancer Survivorship⁠The New England Journal of Medicine⁠Americans with Disabilities Act (ADA.gov)⁠Library of Congress | Civil Rights History Project⁠White Coat, Clenched Fist by Fitzhugh Mullan⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This January, four big AI × Pharma tools deals were announced at the huge JPM Pharma conference that takes over San Francisco every year. OpenAI-backed Chai Discovery (now worth $4B) was somehow at the heart despite being all of 2 years old. The Science team is proud to bring you the first podcast with cofounder Matt McPartlon and product lead Neil Patil to tell the full story! Editor's note: not to be confused with Chai AI, which was another top pod of ours.Pharma suddenly doing big AI tools dealsFor the non-pharma people, JPM is JP Morgan's annual conference for pharma deal-making that takes over San Francisco for a week in January with hundreds of side events, etc. It's a big thing. Tools deals for pharma are also a big (new) thing: companies that start as AI for Pharma usually end up building their own drug pipelines instead, and the reason is something like this: convincing pharma to use your tool requires proof that your tool works. Proof means good targets, maybe with good clinical validation. If you have that, then it's easier to raise money (with a known, if long path to commercialization) or sell (e.g payment in biobucks) for a specific target than it is to sell to lots of companies on a promise that it will work across their portfolios. The “we'll just partner / build our own drug” optionality proved to be the only good path up until January. What changed? In short, the tools got good enough for drug design teams to trust.Good-enough-to-trust unlocks the ability to scale discovery: get more, better candidates into the lab and animal trials faster. More screening for toxicity, better delivery, etc. This means that what you push to the clinic is more likely to succeed.Tools also unlock new capabilities: mechanisms that are very hard or impossible to develop using lab-based discovery. Designing an antibody that precisely triggers a very specific molecular cascade takes many years of trial and error. Designing bi-specific antibodies (that bind to two different proteins) is similarly difficult. Good design tools can unlock this.RJ: The fact that the quality of the model has jumped means you're enabling things you just plain couldn't do. So it's a step change. It's not an efficiency argument at all, or not so much.Matt: Yeah, exactly. It's kind of interesting, even for us — it took me a while to believe in the thesis, actually. I talked to Josh for months before Chai started... It's like, can I beat a mouse, and then can I do what mice can't do? And then how many levels of interaction can you just keep building on top of that?Everyone playing in the structural / binding space has an angle here, and some will be better than others, but Chai is pointing to a different unlock: getting good molecules right out of the gate (meaning they don't then need as much lab work) means that the iteration time is faster. This turns science into engineering: you can design your systems to reduce friction and hill climb towards one-shotting molecules all the way to the clinic.This, per-se, is not a new thesis: a16z articulated a version of this in 2020. What has changed is that structural models became binding models (how well doesn't this molecule bind to this molecule, aka “binding affinity). Binding models unlock design, which has been steadily improving. Chai's observation is that for engineering problems the best product tends to win, and good technology is a necessary but not sufficient condition. Photoshop for moleculesWith that in mind Chai has invested heavily in partnerships that allow them to learn from their Pharma counterparts. What is kind of cool about working so closely and supporting so many of these partners is we get to really learn about what is the stuff that would be helpful in research. So rather than doing research in a vacuum, based on what would hypothetically be cool, we're able to do informed research based on what our partners have just been organically asking us for help with.— Neil Patil, (Chai product lead)This means better UX, such as a molecule editor that is more like a CAD or graphics design program than a chatbot.Their approach has paid off: since June, Chai has announced three more major deals: Lilly, Novartis, argenx, plus an expansion of their Eli Lily program. This episode is too full of quotable moments for a short blog, so tune in to learn about * Why protein tokens have the highest downstream value of any token * Climbing levels of abstraction as models improve * How Pharma, VC, and research are all just portfolio optimization * How better tech changes the whole portfolio * How relentless focus on simplicity leads to scalePlus much more! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

Guest Full Name: Dr. David-Alexandre (“DA”) C. Gros, MD CEODA's Bio:Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and is currently the Executive Chairman of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products since 1935.Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.Company: Eledon Pharmaceuticals, Inc.Ticker: ELDNWebsite: https://eledon.com/About the Company:Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California.

Most bioprocess teams believe a digital twin demands vast datasets and sophisticated models. Ignasi Bofarull-Manzano argues both assumptions are wrong, and that the data already sitting in your Excel files, historians and ELNs is probably enough to start.Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, breaks down what a digital twin actually is, where modeling pays back fastest across the product lifecycle, and how to tell a real business case from an expensive proof of concept.In this episode:Misconceptions about data requirements for digital twins—why quality and context of data matter more than sheer quantity (02:40)Ignasi's journey from curiosity in biology to a career in data science, modeling, and digital twins (04:31)Clear distinctions between digital models, digital shadows, and digital twins, explained with real-world analogies (06:42)How to approach digital development when faced with legacy data silos and scattered analytics (09:56)The importance of starting with a focused business need instead of chasing trends or buzzwords (12:28)Insights into where modeling truly delivers value in the product lifecycle—development versus manufacturing (13:11)Strategies for small companies to leverage digitalization and data from the ground up (15:56)An accessible overview of physics-informed AI, physical AI, and hybrid modeling—and their application in bioprocessing (18:15)The comparative advantages of physics-informed AI versus hybrid models in different bioprocessing contexts (24:45)Smart insight: Do not start with the model. Start with the bottleneck. Identify the business need first, then the decision the model must support, then the minimum data required for that context of use. Build the model offline, concatenate it end to end across unit operations rather than optimizing one in isolation, and prove the value before connecting a single interface. Teams that skip this sequence end up building models because models sound impressive, and those projects get expensive before they get useful.Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del ValEpisodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyConnect with Ignasi Bofarull-Manzano:LinkedIn: www.linkedin.com/in/ignasi-bofarullKörber Pharma website: www.koerber-pharma.comSupport the show

On this Salcedo Storm Podcast:The boys discuss Chris' most recent trip to California, the price of gas and the roel of big oil and Sean is over the heat of summer. 

FRAUDIAN SLIP - 08.05.2026 - #964 BestPodcastintheMetaverse.com Canary Cry News Talk #964 - 08.05.2026 - Recorded Live to 1s and 0s Deconstructing World Events from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! CageRattlerCoffee.com SD/TC email Ike for discount https://CanaryCry.Support   Send address and shirt size updates to canarycrysupplydrop@gmail.com Join the Canary Cry Roundtable This Episode was Produced By:   Executive Producers Mike B*** Rebecca 58*** Grumbriatte*** Sam S*** Sir LX Protocol Baron of the Berrean Protocol***   Producers of TREASURE (CanaryCry.Support) Parker N, Julie S, Rebecca T, Sir Darrin Knight of the Hungry Panda's, Monika   Producers of TIME Timestampers: Jade Bouncerson, Morgan E Clankoniphius Links: JAM   SIR IKE MEGA BOX GIVEAWAY - Rating/Review, screenshot, send to Sir Ike CanaryCrySupplyDrop@gmail.com   MOONBASE/UFOs/RUSSIA/UKRAINE 14:52 V RT Reports SpaceX Crash (X) New Scientist reports on SpaceX Crash (New Scientist)   Scientists warn of secret moon base after spotting over 20 giant UFOs (Dexerto) → PDF of Ukranian Astronomers claim Moon Base (Kiev UA)   EXECUTIVE PRODUCERS 42:18 V   RE-ENCHANTMENT/PHARMEKEIA 01:01:01 V What if Freud Was Right? (The Atlantic) I Told my Therapist I think She's hot (GQ)   BRAIN/MIND CONTROL Earth's Magnetic Field Could Be Controlling Your Mind, Scientists Say—and Ultimately Your Decision-Making (Popular Mechanics)   PRODUCERS 02:14:04 V END

In 1971, President Richard Nixon signed the National Cancer Act, transforming cancer research with an unprecedented federal investment and launching what became known as the War on Cancer. The legislation did not emerge from scientific discovery alone. It was the culmination of decades of relentless advocacy by researchers, philanthropists, journalists, and patients who believed cancer demanded the same national commitment that had put astronauts on the Moon.This episode traces the origins of the cancer survivorship movement by returning to a time when cancer was rarely discussed in public, many physicians withheld diagnoses from their patients, and surgery offered few lasting cures. It follows the pioneering work of pathologist Dr. Sidney Farber, whose early chemotherapy research challenged conventional thinking, and Mary Lasker, whose political strategy, fundraising, and public campaigns helped transform cancer from a private tragedy into a national public health priority. Together, they built the coalition that reshaped federal support for oncology research and forever changed the relationship between science, government, and the American public.The story then turns to journalist and breast cancer survivor Rose Kushner, whose refusal to accept the standard one-step radical mastectomy challenged nearly a century of surgical dogma. Working alongside surgeon Dr. Bernard Fisher, Kushner helped bring evidence-based medicine to breast cancer treatment through randomized clinical trials that demonstrated less invasive surgery could achieve equivalent outcomes. Their efforts changed clinical practice, strengthened informed consent, and helped establish the principle that patients should participate in decisions about their own care.The breakthroughs explored in this episode extended far beyond new treatments. They redefined the role of patients in medicine, accelerated clinical research, and laid the foundation for modern cancer survivorship. The movement that followed would not simply help more people live longer. It would change what surviving cancer meant.RELATED LINKSNational Cancer Institute⁠National Cancer Act of 1971⁠American Cancer Society⁠Dana-Farber Cancer Institute⁠National Library of Medicine⁠The New England Journal of Medicine⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

SpaceX on the move in after-hours trading on the back of its first earnings report since going public. Can investors expect SpaceX to blast off, or will the aerospace giant sink even further below its IPO price?Then, major Pharma earnings from giants like Pfizer and Merck beating Wall Street estimates with Amgen and Eli Lilly on deck. Founder and CEO of Portal Innovations John Flavin lays out the best trades in the Pharma market, and his reaction to Novo Nordisk's slide after disappointing guidance. Plus, why Morgan Stanley is bearish on AMD, digging into Caterpillar earnings, and can McDonald's make a comeback? Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.